Gyre Therapeutics
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Below its 200-day average and near the bottom of the universe on momentum.
- Signal has read STRONG SELL for 2 weeks.
- Its last 5 Sell calls were followed by a 9% average decline over the next quarter.
- Recent price momentum is -41.9% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Short interest has risen to 2.1% of float.
- Analyst tilt is Buy.
- Price is below its 20-day average and below its 60-day average.
- The 20-day average is below the 60-day average, a short-term downtrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2848 U.S. stocks StockVane covers.
Last computed: 2026-11-21 20:27 UTC
Data coverage: 4 of 6 factors. Missing data is not a zero score.
The radar needs all six factors. Available grades are shown below.
Valuation N/A
How expensive the stock is versus earnings, sales and its own 5-year history.
Not enough data to grade this factor.
Growth B+
How fast revenue, profit and free cash flow are compounding.
| Revenue CAGR (3Y) | 4.5% | Better than 45% |
| Net income CAGR (3Y) | 29.7% | Better than 80% |
Profitability B-
How much profit the business keeps from each dollar of sales and capital.
| Gross margin | 95.4% | Better than 98% |
| Operating margin | 9.9% | Better than 51% |
| Net margin | 4.3% | Better than 41% |
| Return on equity | 5.9% | Better than 39% |
| Return on invested capital | 4.5% | Better than 42% |
Momentum D
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | -39.1% | Better than 11% |
| 6-month return | -30.5% | Better than 18% |
| 12-month return (ex latest month) | -22.4% | Better than 13% |
| Distance below 52-week high | 53.9% | Better than 15% |
Financial Health A
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 5.6x | Better than 88% |
| Debt to assets | 0.6% | Better than 95% |
| Interest coverage | 638.8x | Better than 98% |
| Free cash flow / net income | 33.7% | Better than 9% |
Analyst View N/A
What the Street thinks: share of Buy ratings and upside to the average target.
Not enough data to grade this factor.
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 4.52
- Open
- 4.40
- Day range
- 4.13 - 4.51
- Avg price
- 4.28
- Volume
- 240.14K
- Turnover
- 1.03M
- Turnover ratei
- 0.61%
- Volume ratioi
- 0.66
- Amplitudei
- 8.41%
- 52-week rangei
- 3.97 - 9.14
Valuation
- P/Ei
- 210.50
- P/E (TTM)i
- -16.19
- P/Bi
- 4.27
- EPSi
- 0.02
- Book value / shi
- 0.99
- Net profit
- 2.19M
- Net assets
- 107.92M
Share structure
- Market cap
- 460.79M
- Float capi
- 165.70M
- Shares out
- 109.45M
- Float sharesi
- 39.36M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 2006-04-12
53.9% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-243.24K net over the window
Short interest
- Shares short
- 2.24M
- % of floati
- 2.11%
- Days to coveri
- 14.22
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of Gyre Therapeutics (GYRE)?
Gyre Therapeutics last traded at 4.21. This page shows a periodic quote snapshot. Check the displayed quote time.
What is Gyre Therapeutics's market cap?
About 460.79M.
What is the P/E ratio of Gyre Therapeutics?
The trailing twelve-month P/E is -16.19, below its own 5-year average of 62.49 — toward the bottom of its historical range (10.30% percentile). See the Valuation tab for the full history.
Does Gyre Therapeutics pay a dividend?
Gyre Therapeutics does not currently pay a regular dividend.
Is Gyre Therapeutics a buy according to analysts?
The consensus of 1 analysts is a Buy rating, with an average 12-month price target of 18.00, which implies 327.6% upside from the current price. This is not investment advice.
What is Gyre Therapeutics's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Gyre Therapeutics a E (Strong Sell). Below its 200-day average and near the bottom of the universe on momentum. Not investment advice.
Quote time 2026-11-20 20:02:40 · For reference only, not investment advice and not tailored to your situation.
Gyre Therapeutics discussion 0 comments